Upadoz 15mg Tablet Eco Pack, also known as Upadoz 15 Eco Pack Tablet or Upadoz 15 Ecopack Tablet 30's, is a prescription medicine that contains upadacitinib as its active ingredient. Upadoz 15mg composition includes 15 mg of upadacitinib, a Janus kinase (JAK) inhibitor that helps manage various autoimmune and inflammatory diseases by reducing the activity of specific enzymes involved in immune system signalling. Upadoz 15mg tablet uses include the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and other immune-mediated conditions. In adults, the usual Upadoz 15mg dosage is one 15 mg tablet taken once daily or as prescribed by the treating physician.

Upadoz 15mg for ulcerative colitis is also commonly prescribed to help reduce inflammation in the colon, relieve symptoms such as diarrhoea and abdominal pain, minimise disease flare-ups, and support long-term remission. As an oral tablet, Upadoz 15mg Tablet Eco Pack offers a convenient alternative to injectable biologic therapies, helping improve treatment adherence and quality of life.

Patients taking Upadoz 15 Eco Pack Tablet require regular monitoring of blood counts, liver function, and cholesterol levels because the medicine may increase the risk of serious infections, including tuberculosis, herpes zoster (shingles), and pneumonia. It should not be used during pregnancy or breastfeeding unless specifically recommended by a healthcare professional. Patients with a history of heart disease, blood clots, cancer, or chronic infections should inform their doctor before starting treatment.

Substitutes for Upadoz 15 Ecopack Tablet 30's include Rinvoq 15 mg and other brands containing upadacitinib 15 mg. If you are looking for the Upadoz 15 Eco Pack price or Upadoz 15 Eco Pack tablet price, the cost may vary depending on the pharmacy, retailer, and location. You can also purchase Upadoz 15mg Tablet Eco Pack online from trusted and licensed pharmacies with a valid prescription.

upadoz 15mg uses are :

• Treatment of moderate to severe Rheumatoid Arthritis in adults who did not respond well to other medicines.

• Management of Psoriatic Arthritis in adults with an inadequate response to conventional therapies.

• Treatment of moderate to severe Atopic Dermatitis in adults who are candidates for systemic therapy.

• Treatment of active Ankylosing Spondylitis in adults who did not respond adequately to conventional therapies.

• Treatment of moderately to severely active Ulcerative Colitis in adults who have had an inadequate response or intolerance to other medicines.

In autoimmune diseases, the body’s immune system becomes overactive and attacks its own tissues, causing inflammation and damage. Upadacitinib inhibits Janus kinase (JAK) enzymes, which are responsible for transmitting signals that activate inflammation. Blocking these signals reduces immune system overactivity, lowers inflammation, and helps control symptoms of chronic inflammatory conditions.

1. Strong CYP3A4 Inhibitors (Severe)
   Medicines such as ketoconazole or clarithromycin can raise upadacitinib levels in the blood, increasing the risk of infections and serious side effects. Dose adjustment or strict monitoring is required.

2. Strong CYP3A4 Inducers (Severe)
   Drugs like rifampicin, carbamazepine, or phenytoin may reduce upadacitinib levels and weaken its therapeutic effect. Doctors usually avoid this combination.

3. Biologic Immunosuppressants (Severe)
   Combining upadacitinib with drugs like adalimumab, infliximab, or tocilizumab can severely suppress the immune system and increase infection risk. This combination is not recommended.

4. Blood Thinners such as Warfarin or Apixaban (Moderate)
   Upadacitinib may increase the risk of bleeding when taken with anticoagulants. Monitoring for unusual bleeding is advised.

5. Live Vaccines (Moderate)
   Live vaccines, such as MMR or varicella, may not work effectively and can cause infection in immunosuppressed patients. These should be avoided during therapy.

• Store at room temperature (15–30°C).

• Keep away from moisture and direct sunlight.

• Do not use expired or damaged medication.

• Keep out of reach of children.

• Take this medicine exactly as prescribed by your doctor.

• Usually taken once daily, with or without food.

• Swallow the tablet whole; do not crush or chew.

• Your doctor will decide the dose based on your condition and overall health.

Upadoz 15 mg side effects are

Serious:

• Severe infections (tuberculosis, pneumonia, shingles)

• Blood clots (in legs or lungs)

• Chest pain, shortness of breath

• Severe stomach pain or black stools

• Allergic reactions (rash, swelling of face/lips, difficulty breathing)

• Liver problems (yellowing of eyes/skin, dark urine)

Common:

• Nausea

• Cough

• Fever

• Headache

• Stomach pain

• Tiredness

• Upper respiratory tract infections

• Acne.

• Do not start treatment if you have an active infection.

• Your doctor may test for tuberculosis and hepatitis before starting therapy.

• Routine blood tests (liver, kidney, cholesterol, blood counts) are required during treatment.

• Inform your doctor if you are scheduled for vaccinations, as live vaccines are not recommended while on Upadacitinib.

• Always take the medicine as directed; do not stop suddenly without consulting your physician.

1. A Rubbert-Roth et al., “Trial of Upadoz 15mg Tablet or Abatacept in Rheumatoid Arthritis,” The New England Journal of Medicine, [October 2020], demonstrating Upadoz 15mg Tablet’s remission rates compared to abatacept in RA patients https://www.nejm.org/doi/full/10.1056/NEJMoa2008250?

2. R Sanmartí et al., “Upadoz 15mg Tablet for Patients with Rheumatoid Arthritis,” summarizing the phase II BALANCE I & II trials (dose-ranging) and the phase III SELECT trial program for RA regulatory approval https://pmc.ncbi.nlm.nih.gov/articles/PMC10002765/?
   

3. GR Burmester et al., “Safety Profile of Upadoz 15mg Tablet: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease,” Advances in Therapy, [2025], analysing long-term safety across multiple disease indications https://pubmed.ncbi.nlm.nih.gov/36754548/
   

4. C Zhang et al., “Safety profile and dose-dependent adverse events of Upadoz 15mg Tablet: a meta-analysis,” Frontiers in Pharmacology, [2025], highlighting dose-related risks such as hepatic disorders, neutropenia, and acne https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1598972/full